ClinicalTrials.gg
CompletedNCT06973161Updated Apr 8, 2026

ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors

An observational study in Bladder Cancer, Biliary Tract Cancer and Cervical Cancer, sponsored by AstraZeneca. Completed at 27 sites in 12 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-04-08.

Primary conditionnone(registry's first term: Urinary Bladder Neoplasms)Many cancersIs this wrong?The study is open to many cancers (its listed conditions name solid tumors in general), and its title does not single out Urinary Bladder Neoplasms, so we do not take that as its main condition. It is not compared with other studies by condition.

Sponsored by AstraZeneca · Observational

How we know · 2 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
140
Ages
18 Years to 130 Years
Sex
All
01

Study summary

In DESTINY-Pan-Tumor [DP-02], DESTINY CRC02 [DC-02], and DESTINY-Lung01 [DL-01], T-DXd demonstrated tumor response across a broad range of HER2-expressing solid tumors, particularly IHC3+ patients.

This study will use real-world data (RWD) to identify IHC3+ patients in the real world who received standard of care (SoC) and compare them with IHC3+ patients who received T-DXd in the referent trials. The tumors included are: non-small cell lung cancer [NSCLC], colorectal cancer [CRC], endometrial cancer, bladder cancer, epithelial ovarian cancer, cervical cancer, pancreatic cancer, biliary tract cancers, and other tumors.

This is a real-world external control arm (ECA) study to generate evidence on the comparative effectiveness of T-DXd versus real-world (RW) SoC in adult patients with HER2 IHC3+ solid tumors who have received prior systemic treatment. HER2 IHC3+ patients who initiated 5.4mg/kg of T-DXd in the referent trials (DP-02, DC-02, and DL-01) will be compared against IHC3+ patients who received RW SoC. This will be a retrospective observational study which will use secondary real-world data and data collected in the 3 aforementioned trials.

Objectives: The primary objective of this study is to evaluate the comparative effectiveness with respect to overall survival (OS) for T-DXd vs SoC for patients with HER2 IHC3+ expressing solid tumors in two pooled cohorts: one cohort reflecting the tumors in the three referent trials (referred to as the 'tumor agnostic' cohort), consisting of patients with NSCLC, CRC, endometrial, epithelial ovarian, cervical, pancreatic, biliary tract cancers, and other tumors; and a second cohort reflecting the tumors in the DP-02 trial (referred to as 'pan tumor'), consisting of the same tumors but excluding NSCLC and CRC.

02

Conditions studied

  • Bladder Cancer
  • Biliary Tract Cancer
  • Cervical Cancer
  • Endometrial Cancer
  • Ovarian Cancer
  • Pancreatic Cancer
  • Colorectal Cancer
  • Lung Cancer
  • Other Tumors
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 179 (49%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population of interest is adult patients with HER2 IHC3+ unresectable and/or metastatic disease falling within the indications of interest. All IHC3+ patients who initiated 5.4 mg/kg of T-DXd in DP-02, DC-02, or DL-01 for each indication will be included in the T-Dxd arm of this study. To identify RW SoC patients for each indication, relevant eligibility criteria from the corresponding referent trial will be applied and modified for the RW setting where required.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Male or female patients aged 18 years or older at the time of locally advanced, unresectable or disease diagnosis.

Patients diagnosed with one of the following :

Locally advanced, unresectable or metastatic colorectal adenocarcinoma, biliary tract, bladder (urothelial), cervical, endometrial, epithelial ovarian, pancreatic, or other solid tumors, or unresectable and/or metastatic non-squamous NSCLC.

Patients may be included on the basis of de-novo locally advanced, unresectable or metastatic disease diagnosis or progression from initial diagnosis at earlier stages.

Patients must have received at least one line of prior systemic anti-cancer therapy (SACT) therapy in the advanced/ unresectable/ metastatic setting (i.e. excluding adjuvant/ SACT) prior to index.

Index date (start of 2nd or SoC systemic anti-cancer therapy (SACT) treatment) for advanced disease occurring between January 2017 and December 2022.

[CRC patients only] Prior treatment at index with at least one of the following in prior lines of therapy:

Fluoropyrimidine, oxaliplatin, and irinotecan

Anti-epidermal growth factor receptor (EGFR) treatment, if RAS wild-type

Anti-vascular endothelial growth factor (VEGF) treatment

Anti-programmed death-ligand 1 (PD-[L]-1) therapy if tumor is microsatellite instable (MSI)-high/deficient mismatch repair (dMMR), or tumor mutational burden (TMB)-high

[CRC patients only] BRAF wild-type cancer and confirmed RAS status (either mutant or wild type) identified through testing of the primary tumor or metastatic site at any time following initial diagnosis.

IHC3+ -expression confirmed through testing of tumor samples taken in the advanced/ recurrent/ metastatic disease stage. The sample taken closest in time prior to the or at start of the index line of therapy should be used to confirm IHC3+ HER2 status. Positive IHC3+ tests may be the result of testing at the time of sampling by the sites or retrospective testing based on

of 0 or 1 (or score of ≥ 70%8), or missing performance status based on most recently recorded information prior to or at index date.

Patients without recorded history of liver disease, leukaemia, aplastic anaemia or haemophilia at index date.

Patients known to have died must have a complete recorded date of death.

Exclusion criteria

Exclusion Criteria (for the ECA):

Record of other primary (except non-melanoma skin cancer) at any time prior to or after index.

Record of spinal cord compression prior to or at index or active at index (with active CNS metastases determined per physician judgment OR receipt of radiotherapy directed at CNS metastases within 6 months prior to index).

Record of myocardial infarction within 6 months prior to index date or congestive heart failure at any time prior to or at index date.

Record of lung-specific intercurrent illness based on physician judgement prior to or at index date.

History of (non-infectious) ILD/ pneumonitis prior to or at index.

Record of , connective tissue or inflammatory disorders prior to or at index date.

Record of complete pneumonectomy prior to or at index date.

Presence of systemic infection at index date.

Record of prior to or at index date, or active Hep B or Hep C infection at index date.

Treatment with T-DXd or DXd-containing ADC at any time prior to or at index.

Record of pregnancy at or at any time following advanced/ unresectable/ disease diagnosis.

Treatment as part of a clinical trial at any time prior to or at index.

[Pan-tumor patients only] Patients with a record of pleural effusion, ascites or pericardial effusion that requires drainage, peritoneal shunt, or Cell-free and Concentrated Ascites Reinfusion Therapy (CART) at index.

[Colorectal patients only] Patients with record of prior to or at index.

[NSCLC patients only] Treatment with a -targeted therapy (except for pan-HER class tyrosine kinase inhibitors) at any time prior to or at index.

[NSCLC patients only] Record of unstable angina at any time prior to or at index date.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
140 participants (actual)
Patient registry
No

Groups and cohorts

  • Systemic Anticancer Therapy

    Patients who received the existing standard of care systemic anti-cancer therapy (SACT) per routine clinical practice in the real-world setting.

  • Trastuzumab Deruxtecan

    Patients who received 5.4 mg/kg trastuzumab deruxtecan

This study also gives Trastuzumab deruxtecanStudies of Trastuzumab deruxtecanTrastuzumab deruxtecan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Time from the date of first dose of treatment until the date of death due to any cause.

    Time frame: Anticipated to be approximately 11 to 17 months

07

Study locations

27 sites
  • Research Site
    Spartanburg, South Carolina 29303, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Vienna, Austria
  • Research Site
    Liège, Belgium
  • Research Site
    London, Ontario N6A 5A5, Canada
  • Research Site
    Olomouc, Czechia
  • Research Site
    Copenhagen, Denmark
  • Research Site
    Caen, France
  • Research Site
    Lille, France
  • Research Site
    Marseille, France
  • Research Site
    Nice, France
  • Research Site
    Paris, France
  • Research Site
    Saint-Herblain, France
  • Research Site
    Berlin, Germany
  • Research Site
    Essen, Germany
  • Research Site
    Frankfurt, Germany
  • Research Site
    Heidelberg, Germany
  • Research Site
    Würzburg, Germany
  • Research Site
    Meldola, Italy
  • Research Site
    Rome, Italy
  • Research Site
    Porto, Portugal
  • Research Site
    Barcelona, Spain
  • Research Site
    Madrid, Spain
  • Research Site
    Pamplona, Spain
  • Research Site
    Valencia, Spain
  • Research Site
    Leeds, United Kingdom
  • Research Site
    London, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2025 to primary completion in Mar 2026, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2025
First posted
May 15, 2025
StartActual
Jun 10, 2025
Primary completionActual
Mar 17, 2026
CompletionActual
Mar 17, 2026
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06973161
Lead sponsor
AstraZeneca
Collaborators
Daiichi Sankyo, IQVIA Pty Ltd
Responsible party
Sponsor
First posted
May 15, 2025
Start date
Jun 10, 2025
Primary completion
Mar 17, 2026
Completion
Mar 17, 2026
Last update
Apr 8, 2026

Oversight

FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion